Patents by Inventor Marco Gottardis

Marco Gottardis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROSTATE NEOANTIGENS AND THEIR USES
    Publication number: 20240139265
    Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
    Type: Application
    Filed: June 27, 2023
    Publication date: May 2, 2024
    Inventors: Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
  • Methods of Treating Prostate Cancer
    Publication number: 20240000766
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: September 13, 2023
    Publication date: January 4, 2024
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Prostate neoantigens and their uses
    Patent number: 11793843
    Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: October 24, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
  • Methods of Treating Prostate Cancer
    Publication number: 20230149380
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 17, 2022
    Publication date: May 18, 2023
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Methods of Treating Prostate Cancer
    Publication number: 20230098047
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 17, 2022
    Publication date: March 30, 2023
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Methods of Treating Prostate Cancer
    Publication number: 20230078160
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 17, 2022
    Publication date: March 16, 2023
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Methods of Treating Prostate Cancer
    Publication number: 20220071980
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Methods of Treating Prostate Cancer
    Publication number: 20220071979
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Method of treating prostate cancer
    Patent number: 11207311
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A Snyder, Douglas H Yamada
  • PSMA AND STEAP1 VACCINES AND THEIR USES
    Publication number: 20210315986
    Abstract: Disclosed herein are PSMA and/or STEAP1 polynucleotides, polypeptides, vectors, viruses, vaccines, and vaccine combinations, and their uses.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Inventors: Marco Gottardis, Selina Khan, Manuel Alejandro Sepulveda, Douglas H. Yamada, Roland Zahn, Brent Rupnow
  • Bispecific EGFR/IGFIR binding molecules
    Patent number: 10954286
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 23, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20210017252
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: August 6, 2020
    Publication date: January 21, 2021
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
    Patent number: 10774130
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: September 15, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • PROSTATE NEOANTIGENS AND THEIR USES
    Publication number: 20200222478
    Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 16, 2020
    Inventors: Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
  • BISPECIFIC EGFR/IGFIR BINDING MOLECULES
    Publication number: 20190153069
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Application
    Filed: November 30, 2018
    Publication date: May 23, 2019
    Inventors: Stuart EMANUEL, Linda ENGLE, Ray CAMPHAUSEN, Martin C. WRIGHT, Ginger Chao RAKESTRAW, Marco GOTTARDIS, Joan CARBONI
  • METHOD OF TREATING PROSTATE CANCER
    Publication number: 20190022079
    Abstract: Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 24, 2019
    Inventors: Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada
  • Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules
    Patent number: 10183987
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: January 22, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20180265572
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: January 10, 2018
    Publication date: September 20, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Multivalent fibronectin based scaffold domain proteins
    Patent number: 9902762
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 27, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • BISPECIFIC EGFR/IGFIR BINDING MOLECULES
    Publication number: 20180037631
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Application
    Filed: August 23, 2017
    Publication date: February 8, 2018
    Inventors: Stuart EMANUEL, Linda ENGLE, Ray CAMPHAUSEN, Martin C. WRIGHT, Ginger Chao RAKESTRAW, Marco GOTTARDIS, Joan CARBONI